Understanding the US FDA Drug Approval Process

The U.S. Food and Drug Administration (FDA) is responsible for ensuring that drugs marketed in the United States are safe, effective, and of high quality. The process is rigorous and involves multiple stages to verify safety, efficacy, and manufacturing standards.

1. Drug Discovery & Development

• Goal: Identify promising drug candidates through laboratory research.

• Includes:

  • Target identification & validation

  • Compound screening

  • Pre-formulation & formulation studies

• Duration: 2–4 years (varies widely).

2. Preclinical Research

• Purpose: Assess safety before testing in humans.

• Studies:

  • In vitro (cell culture)

  • In vivo (animal models)

• Evaluate:

  • Toxicity

  • Pharmacokinetics (ADME: Absorption, Distribution, Metabolism, Excretion)

  • Pharmacodynamics (mechanism of action)

• Must follow Good Laboratory Practice (GLP).

• If results are promising → Investigational New Drug (IND) Application is filed.

3. Investigational New Drug (IND) Application

• Submitted to FDA before human clinical trials.

• Contains:

  • Preclinical data

  • Manufacturing information

  • Proposed clinical protocols

• FDA reviews safety data within 30 days to approve or place a hold.

4. Clinical Trials

Conducted in three phases (plus a post-marketing Phase IV):

Phase 1 – Safety & Dosage

• Participants: 20–100 healthy volunteers.

• Focus: Safety, tolerability, pharmacokinetics.

• Duration: Several months.

Phase 2 – Efficacy & Side Effects

• Participants: 100–300 patients with the target disease.

• Focus: Effectiveness and short-term side effects.

• Duration: Several months–2 years.

Phase 3 – Confirmation & Monitoring

• Participants: 1,000–3,000 patients.

• Focus: Confirm efficacy, monitor adverse reactions, compare with standard treatments.

• Duration: 1–4 years.

5. New Drug Application (NDA) Submission

• Submitted if clinical trial results support safety & efficacy.

• Includes:

  • All clinical and preclinical data

  • Manufacturing & quality information

  • Proposed labeling

• FDA reviews NDA (standard: 10 months; priority: 6 months).

6. FDA Review & Decision

• FDA teams (medical, statistical, chemistry, pharmacology, labeling experts) evaluate the NDA.

• Inspect manufacturing facilities for Good Manufacturing Practice (GMP) compliance.

• Decision outcomes:

  • Approval

  • Complete Response Letter (requesting more data)

7. Post-Marketing Surveillance (Phase IV)

• Monitor long-term safety & effectiveness in the general population.

• FDA may require additional trials or label updates.

• Adverse events reported via MedWatch.

✅ Summary Flow:
Discovery → Preclinical → IND → Clinical Trials (Phases 1–3) → NDA → FDA Review → Phase IV

🎓 Discover one of the best Pharmaceutical Quality Assurance course available —click below to explore the course that’s shaping future Quality Assurance skills.

https://trcjw.on-app.in/app/oc/306166/trcjw